Dual-target inhibitors of mycobacterial aminoacyl-tRNA synthetases among <i>N</i>-benzylidene-<i>N</i>'-thiazol-2-yl-hydrazines.
Kovalenko OP, Volynets GP, Rybak MY, Starosyla SA, Gudzera OI, Lukashov SS, Bdzhola VG, Yarmoluk SM, Boshoff HI, Tukalo MA.
Effective treatment of tuberculosis is challenged by the rapid development of <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) multidrug resistance that presumably could be overcome with novel multi-target drugs. Aminoacyl-tRNA synthetases (AARSs) are an essential part of protein biosynthesis machinery and attractive targets for drug discovery. Here, we experimentally verify a hypothesis of simultaneous targeting of structurally related AARSs by a single inhibitor. We previously identified a new class of mycobacterial leucyl-tRNA synthetase inhibitors, <i>N</i>-benzylidene-<i>N</i>'-thiazol-2-yl-hydrazines. Molecular docking of a library of novel <i>N</i>-benzylidene-<i>N</i>'-thiazol-2-yl-hydrazine derivatives into active sites of <i>M. tuberculosis</i> LeuRS (<i>Mtb</i>LeuRS) and MetRS (<i>Mtb</i>MetRS) resulted in a panel of the best ranking compounds, which were then evaluated for enzymatic potency. Screening data revealed 11 compounds active against <i>Mtb</i>LeuRS and 28 compounds active against <i>Mtb</i>MetRS. The hit compounds display dual inhibitory potency as demonstrated by IC<sub>50</sub> values for both enzymes. Compound <b>3</b> is active against <i>Mtb</i> H37Rv cells in <i>in vitro</i> bioassays.